

BIOFRONTERA INC.

ISIN: US09077D2099

WKN: 09077D209

Asset Class: Stock

Company

2024/08/16 22:00:00



Price

1.36 USD

Difference ▲ 17.24%(0.20)

Contact Details

BIOFRONTERA INC.

Tel: +1-781-245-1325

--

Fax: +

120 Presidnetial Way, Suite 330

Web: <http://www.biofrontera-us.com>

01801 Woburn

E-mail: info-us@biofrontera.com

Company Profile

Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	23,075,000		43,140,000		46,421,000	
Common stock capital		2,000		27,000		17,000
Fixed assets	4,857,000		7,744,000		6,798,000	
Equity capital of a company		4,793,000		23,878,000		11,338,000
Cash and cash equivalents	1,343,000		17,208,000		24,545,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		18,088,000		20,894,000		13,836,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		5,051,000		6,112,000		28,045,000
Different income		-		-		-
Other liabilities		4,247,000		5,264,000		28,045,000
Total assets	27,932,000	27,932,000	50,884,000	50,884,000	53,219,000	53,219,000

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	85	81	69
Equity ratio	17.16%	46.93%	21.30%
Debt-equity ratio	482.77%	113.10%	369.39%

Others

	2023	2022	2021
Tax Expense Rate	-0.07%	-5.26%	-0.15%

BIOFRONTERA INC.

ISIN: US09077D2099

WKN: 09077D209

Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	34,071,000	28,674,000	24,100,000
Net income	-20,131,000	-640,000	-37,713,000
EBIT	-17,870,766	-375,624	-33,936,174
Operating income before taxes	-20,117,000	-608,000	-37,657,000
Cash Flow	-24,895,000	-16,199,000	-26,715,000
Net interest income	-468,000	-195,000	-344,000
Research and development expenses	77,000	-	-
Income taxes	14,000	32,000	56,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	364,560	321,963	317,666

Board of Directors

Members of Management Board

Beth Hoffman	Member of Board of Directors
Heikki Lanckriet	Member of Board of Directors
John Borer	Member of Board of Directors
Kevin Weber	Member of Board of Directors
Dr. Hermann Lübbert	Chairman of Managing Board
Fred Leffler	Member of Executive Committee